A rare cause of acute urinary retention— Primary malignant melanoma of prostate
Kalpesh Parmar(
Department of Urology, PGIMER, Chandigarh, India
Abstract: Acute urinary retention is commonly seen in elderly male patient due to benign enlargement of prostate. We report a 65-year-old male presenting with acute urinary retention diagnosed to have primary malignant melanoma of prostate. Primary malignant melanoma of genitourinary tract is very uncommon diagnosis in urology and prostate involvement is extremely rare. Till now only five cases have been reported.
Key words:
Urinary retention
Malignant melanoma
Transurethral resection of prostate aggressive
Prostate
收稿日期: 2017-12-28
修回日期: 2018-05-21
接受日期: 2018-06-06
出版日期: 2019-01-12
发布日期: 2019-09-23
整期出版日期: 2019-10-20
[1]
Stein BS, Kendall AR . Malignant melanoma of the genitourinary tract. J Urol 1984; 192:859-68.
[2]
Nguyen AT, Kavolius JP, Russo P, Grimaldi G, Katz J, Brady MS . Primary genitourinary melanoma. Urology 2001; 57:633-8.
[3]
Wong JA, Bell DG . Primary malignant melanoma of the prostate: case report and review of the literature. Can J Urol 2006; 13:3053-6.
[4]
Wang CJ . Follow-up of primary malignant melanoma of the prostate. J Urol 2001; 166:214.
[1]
Antonio Benito Porcaro, Giovanni Novella, Matteo Balzarro, Guido Martignoni, Matteo Brunelli, Giovanni Cacciamani, Maria A. Cerruto, Walter Artibani. Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study
[2]
Zhixiang Wang, Bing Liu, Xiaofeng Gao, Yi Bao, Yang Wang, Huamao Ye, Yinghao Sun, Linhui Wang. Laparoscopic ureterolysis with simultaneous ureteroscopy and percutaneous nephroscopy for treating complex ureteral obstruction after failed endoscopic intervention: A technical report
[3]
Louis R. Kavoussi. News from leading international academic urology departments
[4]
Rikiya Taoka, Yoshiyuki Kakehi. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia
[5]
Cheuk Fan Shum, Weida Lau, Chang Peng Colin Teo. Medical therapy for clinical benign prostatic hyperplasia:a1 Antagonists, 5a reductase inhibitors and their combination
[6]
Sufyan Suleman, Gong-Hong We. Combined immunotherapy for advanced prostate cancer:Empowering the T cell army
[7]
Kok Kit Ng, Foo Cheong Ng. The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men
[8]
Jonathan Shunming Teo, Yee Mun Lee, Henry Sun Sien Ho. An update on transurethral surgery for benign prostatic obstruction
[9]
Yuejiao Huang, Chun Cheng, Chong Zhang, Yonghui Zhang, Miaomiao Chen, Douglas W. Strand, Ming Jiang. Advances in prostate cancer research models: From transgenic mice to tumor xenografting models
[10]
Rishi R. Sekar, Claire M. De La Calle, Dattatraya Patil, Sarah A. Holzman, Yoram Baum, Umer Sheikh, Jonathan H. Huang, Adeboye O. Osunkoya, Brian P. Pollack, Haydn T. Kissick, Kenneth Ogan, Viraj A. Master. Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival
Viewed
Full text
Abstract
Cited
Shared
Discussed
